Hepatic arterial iodine-131-labeled metuximab injection combined with chemoembolization for unresectable hepatocellular carcinoma: Interim safety and survival data from 110 patients

Cancer Biotherapy and Radiopharmaceuticals

Volumn 25, Issue 6, 2010, Pages 657-663

  Wu, Lu ^a   Yang, Ye Fa ^a   Ge, Nai Jian ^a   Shen, Shu Qun ^a   Liang, Jun ^a   Wang, Yi ^a   Zhou, Wei Ping ^a   Shen, Feng ^a   Wu, Meng Chao ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Antibody; cancer; iodine 131; radioimmunotherapy; radiopharmaceuticals

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; BILIRUBIN; IMMUNOGLOBULIN G1 ANTIBODY; IODINE 131; METUXIMAB I 131; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALCOHOLISM; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CHEMOEMBOLIZATION; CHILL; CONTROLLED STUDY; CYTOTOXICITY; DIARRHEA; DRUG SAFETY; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEPATIC ARTERY; HEPATITIS B; HEPATITIS C; HUMAN; KAPLAN MEIER METHOD; LEUKOCYTE; LEUKOCYTE COUNT; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PAIN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE; THROMBOCYTE COUNT; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; HEPATIC ARTERY; HUMANS; IMMUNOTOXINS; INJECTIONS, INTRA-ARTERIAL; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 78651319264     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2010.0801     Document Type: Article

References (41)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74.
2. El Serag HB, Mason AC Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745.
3. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in pa-tients with cirrhosis. N Engl J Med 1996;334:693.
4. Shiina S, Teratani T, Obi S, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005;129: 122.
5. Lin SM, Lin CJ, Lin CC, et al. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3cm or less. Gut 2005;54:1151.
6. Ikai I, Arii S, Kojiro M, et al. Reevaluation of prognostic factors for survival after liver resection in patients with he-patocellular carcinoma in a Japanese nationwide survey. Cancer 2004;101:796.
7. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in pa-tients with unresectable hepatocellular carcinoma: A rando-mised controlled trial. Lancet 2002;359:1734.
8. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with ad-vanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25.
9. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N EnglJ Med 2008;359:378.
10. Cheng JC, Wu JK, Lee PC, et al. Biologic susceptibility of hepatocellular carcinoma patients treated with radiotherapy to radiation-induced liver disease. Int J Radiat Oncol Biol Phys 2004;60:1502.
11. Thomas E, Chapet O, Kessler ML, et al. Benefit of using biologic parameters (EUD and NTCP) in IMRT optimization for treatment of intrahepatic tumors. Int J Radiat Oncol Biol Phys 2005;62:571.
12. Hawkins MA, Dawson LA. Radiation therapy for hepato-cellular carcinoma: From palliation to cure. Cancer 2006;106: 1653.
13. Chen ZN, Mi L, Xu J, et al. Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: Clinical phase I/II trials. Int J Radiat Oncol Biol Phys 2006;65:435.
14. Zhang Z, Bian H, Feng Q, et al. Biodistribution and locali-zation of iodine-131-labeled metuximab in patients with hepatocellular carcinoma. Cancer Biol Ther 2006;5:318.
15. Toole BP. Emmprin (CD147), a cell surface regulator of matrix metalloproteinase production and function. Curr Top Dev Biol 2003;54:371.
16. Chen ZN, Shang P, Li Y, et al. (inventors); NTD Patent & Trademark Agency Ltd., Beijing Office (assignee). HAb18G/CD147, it's agonist and application. Chinese patent ZL01131735.3, 2001 Sep 28; PCT international patent WO02/094875. 2002 May 27.
17. Zhang Q, Chen X, Zhou J, et al. CD147, MMP-2, MMP-9 and MVD-CD34 are significant predictors of recurrence after liver transplantation in hepatocellular carcinoma patients. Cancer Biol Ther 2006;5:808.
18. Xu H, Shen ZY, Chen XG, et al. A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology 2007;45:269.
19. Llovet JM, Di Bisceglie AM, Bruix J, et al. Panel of Experts in HCC-Design Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100:698.
20. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421.
21. Colli A, Fraquelli M, Casazza G, et al. Accuracy of ultraso-nography, spiral CT, magnetic resonance, and alpha-feta-protein in diagnosing hepatocellular carcinoma: A systemic review. Am J Gastroenterol 2006;101:513.
22. Katyal S, Oliver JH 3rd, Peterson MS, et al. Extrahepatic metastases of hepatocellular carcinoma. Radiology 2000;216: 698.
23. Chen ZN, Liu YF. Monoclonal antibody HAb18 to human hepatoma. Monoclonal Antibodies 1990;8:11.
24. Liu YF, Chen ZN, Ji YY. Localization of hepatocellular carcinoma with monoclonal antibodies. Zhonghua Yi Xue Za Zhi 1991;71:362.
25. Chen ZN, Xing JL, Zhang SH (inventors); NTD Patent & Trademark Agency Ltd., Beijing Office (assignee). Anti-human hepatoma monoclonal antibody HAb18 light/heavy chain variable region gene, and use thereof. Chinese patent ZL02114471.0, 2002 March 15; PCT international patent WO03/078469. 2003 March 17.
26. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207.
27. Raoul J, Guyader D, Bretagne JF, et al. Prospective ran-domized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of he-patocellular carcinoma. Hepatology 1997;26:1156.
28. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164.
29. Yamada K, Izaki K, Sugimoto K, et al. Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2003;57:113.
30. Ueno K, Miyazono N, Inoue H, et al. Transcatheter arterial chemoembolization therapy using iodized oil for patients with unresectable hepatocellular carcinoma: Evaluation of three kinds of regimens and analysis of prognostic factors. Cancer 2000;88:1574.
31. Yamada R, Kishi K, Sonomura T, et al. Transcatheter arterial embolization in unresectable hepatocellular carcinoma. Cardiovasc Intervent Radiol1990;13:135.
32. Nakamura H, Hashimoto T, Oi H, et al. Treatment of he-patocellular carcinoma by segmental hepatic artery injection of adriamycin-in-oil emulsion with overflow to segmental portal veins. Acta Radiol 1990;31:347.
33. Chen MS, Li JQ, Zhang YQ, et al. High-dose iodized oil transcatheter arterial chemoembolization for patients with large hepatocellular carcinoma. World J Gastroenterol 2002; 8:74.
34. Wang MQ. Transcatheter arterial chemoembolization for 850 patients with primary hepatocellular carcinoma. Chin J Med Imaging Technol 1996;12:23.
35. Pelletier G, Ducreux M, Gay F, et al. Treatment of unresectable hepatocellular carcinoma with lipiodol che-moembolization: A multicenter randomized trial. J Hepatol 1998;29:129.
36. Chen ZN, Yang Z, Mi L, et al. The structural and functional analysis of the hepatoma related factor, HAb18G. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 1999;15:34.
37. Li Y, Shang P, Qian AR, et al. Inhibitory effects of antisense RNA of HAb18G/CD147 on invasion of hepatocellular carcinoma cells in vitro. World J Gastroenterol 2003;9:2174.
38. Jiang JL, Zhou Q, Yu MK, et al. The involvement of HAb18G/CD147 in regulation of store-operated calcium entry and metastasis of human hepatoma cells. J Biol Chem 2001;267:46870.
39. Jiang JL, Yu MK, Chen ZN, et al. cGMP-regulated store-operated calcium entry in human hepatoma cells. Cell Biol Int 2001;25:993.
40. Huang BC, Shang P, Qian AR, et al. Bio-panning of antag-onistic peptides against HAb18G/CD147 and their function of anti-hepatoma invasion. Zhonghua Zhong Liu Za Zhi 2003;25:111.
41. Jiang JL, Chan HC, Zhou Q, et al. HAb18G/CD147-mediated calcium mobilization and hepatoma metastasis require both C-terminal and N-terminal domains. Cell Mol Life Sci 2004;61:2083.